[Form 4] ADMA BIOLOGICS, INC. Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
ADMA Biologics (ADMA) reported insider equity activity by its President, CEO and Director, Adam S. Grossman. On 11/19/2025, he exercised a stock option to acquire 15,000 shares of common stock at an exercise price of $5.40 per share, then sold 15,000 shares and an additional 6,000 shares of common stock at a sale price of $16.00 per share. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan entered into on December 5, 2024. Following these transactions, he directly owned 2,013,850 shares of common stock, with additional indirect ownership of 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC, along with 735,950 stock options and multiple tranches of unvested RSUs that vest over four-year schedules.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 21,000 shares ($336,000)
Net Sell
6 txns
Insider
Grossman Adam S
Role
President and CEO
Sold
21,000 shs ($336K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 15,000 | $0.00 | -- |
| Exercise | Common Stock | 15,000 | $5.40 | $81K |
| Sale | Common Stock | 15,000 | $16.00 | $240K |
| Sale | Common Stock | 6,000 | $16.00 | $96K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 735,950 shares (Direct);
Common Stock — 2,034,850 shares (Direct);
Common Stock — 1,143,426 shares (Indirect, See Footnote)
Footnotes (1)
- Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer. The price reported in Column 4 is the price at which the shares were sold. Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (continued from footnote 3) (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 981,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth. These shares are owned by Hariden, LLC ("Hariden"). The reporting person is the managing member of Hariden. The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.
